{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:27Z","timestamp":1780750767491,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":26,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_16","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:00:46Z","timestamp":1753707646000},"page":"243-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vivo Evaluation of Single- and Multi-Exon-Skipping in mdx52 Mice"],"prefix":"10.1007","author":[{"given":"Chaitra","family":"Sathyaprakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hotake","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Tominari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Echigoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"6","key":"16_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919\u2013928","journal-title":"Cell"},{"issue":"3","key":"16_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32(3):671\u2013688. https:\/\/doi.org\/10.1016\/j.ncl.2014.05.002","journal-title":"Neurol Clin"},{"issue":"5","key":"16_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/1389201043376706","volume":"5","author":"V Arora","year":"2004","unstructured":"Arora V, Devi GR, Iversen PL (2004) Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 5(5):431\u2013439. https:\/\/doi.org\/10.2174\/1389201043376706","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"16_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102(1):198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"16_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65(6):667\u2013676. https:\/\/doi.org\/10.1002\/ana.21627","journal-title":"Ann Neurol"},{"issue":"13","key":"16_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"issue":"6","key":"16_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","volume":"14","author":"A Touznik","year":"2014","unstructured":"Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809\u2013819. https:\/\/doi.org\/10.1517\/14712598.2014.896335","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"16_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nrneurol.2016.180","volume":"12","author":"JJ Dowling","year":"2016","unstructured":"Dowling JJ (2016) Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat Rev Neurol 12(12):675\u2013676. https:\/\/doi.org\/10.1038\/nrneurol.2016.180","journal-title":"Nat Rev Neurol"},{"issue":"437","key":"16_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713","volume":"10","author":"H Komaki","year":"2018","unstructured":"Komaki H, Nagata T, Saito T, Masuda S, Takeshita E, Sasaki M et al (2018) Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med 10(437):eaan0713. https:\/\/doi.org\/10.1126\/scitranslmed.aan0713","journal-title":"Sci Transl Med"},{"issue":"4912","key":"16_CR10","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.2662404","volume":"244","author":"P Sicinski","year":"1989","unstructured":"Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244(4912):1578\u20131580. https:\/\/doi.org\/10.1126\/science.2662404","journal-title":"Science"},{"issue":"2","key":"16_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34(2):135\u2013144. https:\/\/doi.org\/10.1002\/mus.20586","journal-title":"Muscle Nerve"},{"issue":"3","key":"16_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ et al (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293\u2013299. https:\/\/doi.org\/10.1002\/humu.20918","journal-title":"Hum Mutat"},{"issue":"2","key":"16_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1006\/bbrc.1997.7328","volume":"238","author":"E Araki","year":"1997","unstructured":"Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I et al (1997) Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun 238(2):492\u2013497. https:\/\/doi.org\/10.1006\/bbrc.1997.7328","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"16_CR14","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","volume":"22","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T et al (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-\u03b12 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22(24):4914\u20134928. https:\/\/doi.org\/10.1093\/hmg\/ddt341","journal-title":"Hum Mol Genet"},{"issue":"11","key":"16_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T et al (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18(11):1995\u20132005. https:\/\/doi.org\/10.1038\/mt.2010.186","journal-title":"Mol Ther"},{"issue":"13","key":"16_CR16","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1093\/hmg\/6.13.2195","volume":"6","author":"S Kameya","year":"1997","unstructured":"Kameya S, Araki E, Katsuki M, Mizota A, Adachi E, Nakahara K et al (1997) Dp260 disrupted mice revealed prolonged implicit time of the b-wave in ERG and loss of accumulation of beta-dystroglycan in the outer plexiform layer of the retina. Hum Mol Genet 6(13):2195\u20132203. https:\/\/doi.org\/10.1093\/hmg\/6.13.2195","journal-title":"Hum Mol Genet"},{"key":"16_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102288","volume":"216","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Kuniishi H, Sakai K, Fukushima Y, Du X, Yamashiro K et al (2022) Brain Dp140 alters glutamatergic transmission and social behaviour in the mdx52 mouse model of Duchenne muscular dystrophy. Prog Neurobiol 216:102288. https:\/\/doi.org\/10.1016\/j.pneurobio.2022.102288","journal-title":"Prog Neurobiol"},{"issue":"1","key":"16_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajmg.1320570107","volume":"57","author":"TW Prior","year":"1995","unstructured":"Prior TW, Bartolo C, Pearl DK, Papp AC, Snyder PJ, Sedra MS et al (1995) Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet 57(1):22\u201333","journal-title":"Am J Hum Genet"},{"issue":"4","key":"16_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A, Shiba N, Miyazaki D, Nishizawa H, Inaba Y, Fueki N et al (2017) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463. https:\/\/doi.org\/10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"issue":"1","key":"16_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/nat.2013.0451","volume":"24","author":"Y Echigoya","year":"2014","unstructured":"Echigoya Y, Yokota T (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 24(1):57\u201368. https:\/\/doi.org\/10.1089\/nat.2013.0451","journal-title":"Nucleic Acid Ther"},{"issue":"7","key":"16_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jocn.2006.12.012","volume":"15","author":"A Nakamura","year":"2008","unstructured":"Nakamura A, Yoshida K, Fukushima K, Ueda H, Urasawa N, Koyama J et al (2008) Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 15(7):757\u2013763. https:\/\/doi.org\/10.1016\/j.jocn.2006.12.012","journal-title":"J Clin Neurosci"},{"issue":"2","key":"16_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T et al (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4(2):e225. https:\/\/doi.org\/10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"issue":"34","key":"16_CR23","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T et al (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 109(34):13763\u201313768. https:\/\/doi.org\/10.1073\/pnas.1204638109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"16_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Krieg AM (2017) FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen saga. Nucleic Acid Ther 27(1):1\u20133. https:\/\/doi.org\/10.1089\/nat.2016.0657","journal-title":"Nucleic Acid Ther"},{"key":"16_CR25","doi-asserted-by":"publisher","unstructured":"Railroading at the FDA (2016). Nat Biotechnol 34(11):1078. https:\/\/doi.org\/10.1038\/nbt.3733","DOI":"10.1038\/nbt.3733"},{"issue":"15","key":"16_CR26","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","volume":"24","author":"C Godfrey","year":"2015","unstructured":"Godfrey C, Muses S, McClorey G, Wells KE, Coursindel T, Terry RL et al (2015) How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol Genet 24(15):4225\u20134237. https:\/\/doi.org\/10.1093\/hmg\/ddv155","journal-title":"Hum Mol Genet"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:08:02Z","timestamp":1780747682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":26,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}